Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 554

1.

A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.

Rubino M, Summers KH, Puenpatom A, Fu C, Ohsfeldt RL, Ben-Joseph RH.

J Manag Care Pharm. 2011 Jun;17(5):367-76.

2.

Daily average consumption of 2 long-acting opioids: an interrupted time series analysis.

Puenpatom RA, Szeinbach SL, Ma L, Ben-Joseph RH, Summers KH.

Am Health Drug Benefits. 2012 Jan;5(1):52-60.

3.
4.

Measuring economic impact of applying daily average consumption limits.

Flavin BM, Nishida LM, Karbowicz SH, Renner ME, Leonard RJ.

J Manag Care Pharm. 2014 Feb;20(2):159-64.

5.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.

Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

Curr Med Res Opin. 2014 Aug;30(8):1589-98. doi: 10.1185/03007995.2014.915803. Epub 2014 Apr 24.

PMID:
24738694
6.

Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.

Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH.

Clin Ther. 2013 May;35(5):659-72. doi: 10.1016/j.clinthera.2013.03.016. Epub 2013 Apr 13.

PMID:
23587608
9.

Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.

Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M.

J Manag Care Pharm. 2003 May-Jun;9(3):223-31.

10.

Implementation of an opioid management initiative by a state Medicaid program.

Garcia MM, Angelini MC, Thomas T, Lenz K, Jeffrey P.

J Manag Care Spec Pharm. 2014 May;20(5):447-54.

11.

Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain.

Anastassopoulos KP, Chow W, Tapia CI, Baik R, Ackerman SJ, Biondi D, Kim MS.

J Manag Care Pharm. 2012 Oct;18(8):615-26.

12.

Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.

Neil N, Merchant S, Provenzano D, Ogden K, Mody SH.

J Med Econ. 2013;16(2):307-17. doi: 10.3111/13696998.2012.756401. Epub 2012 Dec 14.

PMID:
23216013
13.

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.

Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

J Med Econ. 2014 Apr;17(4):279-87. doi: 10.3111/13696998.2014.897628. Epub 2014 Mar 7.

PMID:
24559196
14.

Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.

Sloan P, Slatkin N, Ahdieh H.

Support Care Cancer. 2005 Jan;13(1):57-65. Epub 2004 Nov 9.

PMID:
15538638
15.

Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.

Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.

J Med Econ. 2012;15(1):87-95. doi: 10.3111/13696998.2011.629261. Epub 2011 Oct 28.

PMID:
22032675
16.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

17.

Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone.

Ben-Joseph R, Bell JA, Brixner D, Kansal A, Paramore C, Chitnis A, Holly P, S Burgoyne D.

J Manag Care Spec Pharm. 2016 Apr;22(4):358-66. doi: 10.18553/jmcp.2016.22.4.358.

19.

Use of oral oxymorphone in the elderly.

Guay DR.

Consult Pharm. 2007 May;22(5):417-30. Review.

PMID:
17658959
20.

Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, Teitelbaum A.

J Manag Care Spec Pharm. 2014 May;20(5):485-93.

Supplemental Content

Support Center